FDA Reverses Course on NMN, Reinstates Dietary Supplement Status After Legal Challenge
核心洞察
The FDA has officially reinstated NMN (搜索) (beta-nicotinamide mononucleotide) as a legal dietary ingredient, sending confirmation letters to manufacturers SyncoZymes (搜索) and Inner Mongolia Kingdomway Pharmaceutical Limited (搜索) in December 2024.
This reversal follows a contentious regulatory battle that began in late 2022 when FDA initially excluded NMN (搜索) from dietary supplement definition due to prior drug investigation, prompting a citizen petition and lawsuit from industry groups.
The decision provides regulatory clarity for the anti-aging supplement market, though industry advocates warn similar uncertainty remains for other next-generation ingredients like peptides that may face drug preclusion challenges.
The U.S. Food and Drug Administration has officially reversed its position on nicotinamide mononucleotide (NMN (搜索)), confirming in December 2024 letters to manufacturers that the anti-aging ingredient can be lawfully marketed as a dietary supplement. This decision ends a two-year regulatory battle that highlighted ongoing tensions between pharmaceutical development and supplement innovation.
Regulatory Reversal Restores Market Access
The FDA sent letters to SyncoZymes (搜索) (NDIN 1247) and Inner Mongolia Kingdomway Pharmaceutical Limited (搜索) (NDIN 1259) on December 2, 2024, expressly reinstating their successful new dietary ingredient notifications (NDINs). Both companies had initially received FDA approval in May 2022, with the agency agreeing that NMN (搜索) met the definition of a dietary ingredient and was safe for use.
However, in November 2022, FDA reversed its position, informing both companies that NMN (搜索) was not allowed as a dietary ingredient because of its prior investigation as a drug. This decision invoked the controversial drug preclusion clause of the Dietary Supplement Health and Education Act (DSHEA), which prohibits ingredients first researched as drug candidates from subsequent use as dietary supplements.
Legal Challenge Forces Agency Response
The regulatory uncertainty prompted swift industry action. The Natural Products Association (搜索) (NPA) and the Alliance for Natural Health USA (搜索) (ANH) filed a joint citizen petition on March 7, 2023, requesting that FDA determine NMN (搜索) is not excluded from the dietary supplement definition or commit to enforcement discretion regarding NMN supplement sales.
After FDA stated in September 2023 that it had been unable to reach a decision due to "competing agency priorities," NPA escalated the matter by filing a lawsuit against the agency in August 2024. The legal proceedings were temporarily stayed in October 2024 when U.S. District Judge Paul L. Friedman granted a pause to allow FDA to evaluate the NMN (搜索) citizen petition, accompanied by a period of enforcement discretion for NMN-containing products labeled as dietary supplements.
Scientific Significance and Market Impact
NMN (搜索), part of the vitamin B3 family along with nicotinamide riboside (NR (搜索)), has been shown to enhance levels of nicotinamide adenine dinucleotide (NAD+) in cellular systems. Boosting NAD+ levels has demonstrated significant benefits in staving off cellular aging (搜索), making NMN a prominent ingredient in the anti-aging supplement market.
Interest in NMN (搜索) intensified after research by prominent anti-aging researcher David Sinclair elucidated a cellular transporter mechanism. This discovery addressed previous arguments from NR (搜索) proponents that NMN required conversion to NR before crossing cell membranes.
Industry Response and Future Implications
Daniel Fabricant, PhD, president and CEO of NPA, characterized the outcome as "an unequivocal victory on this specific issue," noting that "FDA has provided more clarity on the drug preclusion clause in DSHEA than ever before."
However, industry leaders acknowledge broader challenges remain. "NPA's successful effort to establish the legitimacy of NMN (搜索) required extraordinary investments, including the filing of a formal citizen petition and subsequent litigation against FDA," Fabricant stated. "Absent congressional action, the same uncertainty now looms over peptides and other next-generation ingredients that may become entangled in investigational new drug applications, chilling research, deterring investment, undermining innovation and limiting consumer choice."
The Council for Responsible Nutrition (搜索) had previously criticized FDA's approach, with president and CEO Steve Mister stating that the agency "missed a pivotal opportunity to bring clarity and balance to the line between pharmaceuticals and dietary supplements."
Ongoing Legislative Efforts
NPA indicated it will continue working with congressional offices to advance a targeted legislative fix to the drug preclusion clause, which the organization says has been inconsistently interpreted and applied in ways that threaten lawful supplement ingredients. The association emphasizes that regulatory clarity is essential to ensure DSHEA continues to function as Congress intended by providing a predictable, science-based framework that protects consumers while allowing responsible innovation to flourish.